Home › Burkitt Lymphoma › Texas
Burkitt Lymphoma clinical trials in Texas
24 studies for Burkitt Lymphoma are looking for participants at sites in Texas.
Cities in Texas
- Houston21 studies
- Dallas7 studies
- San Antonio7 studies
- Austin5 studies
- Fort Worth4 studies
- El Paso4 studies
- Corpus Christi4 studies
- Lubbock3 studies
- Killeen3 studies
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- and 10 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Houston Methodist Hospital, Houston
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- and 7 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Sep 17, 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Methodist Children's Hospital, San Antonio
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Sep 16, 2026 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Baylor University Medical Center, Dallas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- and 10 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- and 12 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- University of Texas, Southwestern, Dallas
- Baylor Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 15 and older · All sexes · Updated Aug 10, 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT01371630Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jul 13, 2026 · NCT07109219Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 14 and older · All sexes · Updated May 20, 2026 · NCT02877303Study of SGR-1505 in Mature B-Cell Neoplasms
- University of Texas Southwestern, Dallas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Sarah Cannon - St. David's South Austin Medical Center, Austin
- MD Anderson Cancer Center, Houston
- Sarah Cannon - Texas Transplant Institute at Methodist Hospital, San Antonio
RecruitingPhase 1/2
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- The University of Texas M. D. Anderson Cancer Center, Houston
- Methodist Healthcare System, San Antonio
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.